Fratricide (Immunology)

Fratricide in immunology (from the Latin fratricidium, "killing of one's brother") is the process by which activated T lymphocytes or natural killer (NK) cells lyse sibling lymphocytes of the same lineage or clonal specificity. First characterized in the 1990s by Michael J. Bevan, Peter Walden, Herman N. Eisen, and Shyr-Te Ju during studies of cytotoxic T-lymphocyte (CTL) peptide presentation and activation-induced cell death (AICD), immunological fratricide serves physiologically as a negative-feedback homeostatic brake that contracts clonally expanded effector T-cell populations after pathogen clearance and prevents immunopathology during high-dose antigen exposure. In contemporary clinical oncology, fratricide has emerged as a central bioengineering barrier in chimeric antigen receptor T-cell (CAR-T) immunotherapy—both because CAR-T cells targeted against T-cell malignancies (CD7, CD5, CD3, or TCRβ1/2) self-destruct by recognizing the pan-T-cell antigen on their own membranes, and because CAR-T cells in solid or liquid tumors strip target antigens from cancer cells via trogocytosis and subsequently become targets for killing by sibling CAR-T cells.

Immunological fratricide operates through three distinct molecular pathways depending on whether killing is triggered by shared death receptors, trogocytosed peptide–major histocompatibility complex (pMHC) ligands, or endogenous pan-lineage surface markers:

1. Fas–FasL Activation-Induced Cell Death (AICD)

When naive T cells first encounter cognate antigen on a dendritic cell, IL-2 signaling promotes clonal expansion while upregulating the anti-apoptotic protein c-FLIP (cellular FLICE-like inhibitory protein) and Bcl-x_L, rendering early effector T cells resistant to apoptosis. However, upon repeated TCR restimulation after several rounds of division, NFAT, NF-κB, and Egr2/Egr3 drive high-level transcription of Fas Ligand (FASLG / CD95L) while IL-2 withdrawal downregulates c-FLIP. When crowded activated T cells contact one another in lymph nodes or inflamed tissues, FasL on one T cell ligates trimeric Fas (CD95) on a neighboring T cell (fratricide) or on the same cell (autocrine suicide). Fas ligation recruits the adaptor FADD (Fas-associated protein with death domain) and procaspase-8 into the death-inducing signaling complex (DISC), triggering caspase-8 auto-cleavage, Bid truncation (tBid), mitochondrial outer membrane permeabilization, and executioner caspase-3/7 apoptosis. Inherited loss-of-function mutations in FAS, FASLG, or CASP10 abolish this homeostatic fratricide, causing autoimmune lymphoproliferative syndrome (ALPS) characterized by massive accumulation of double-negative (CD4⁻CD8⁻TCRαβ⁺) T cells, splenomegaly, and autoimmune cytopenias.

2. Trogocytosis-Driven Perforin/Granzyme CTL Fratricide

In 1999, Jing-Feng Huang, Yiping Yang, Herman N. Eisen, and Jonathan Sprent, together with Michael J. Bevan and Denis Hudrisier, discovered a second, antigen-specific form of fratricide unique to CD8⁺ cytotoxic T lymphocytes. When a CD8⁺ CTL engages its cognate peptide–MHC class I (pMHC-I) complex on an infected target cell or dendritic cell across an immunological synapse, TCR internalizes a patch of the target cell plasma membrane via trogocytosis. Within minutes, the CTL becomes cross-dressed with the very pMHC-I complexes it recognizes.

If the local density of antigen and sibling CTLs is high, a second CTL of the same clonal specificity binds the trogocytosed pMHC-I complexes displayed on the first CTL's surface and Polarizes its microtubule-organizing center (MTOC) to release perforin-1 and granzyme B into the synaptic cleft, lysing the sibling CTL. High-avidity CTL clones—which strip the largest quantities of pMHC-I from target cells—are preferentially eliminated by trogocytic fratricide, explaining why supra-optimal antigen doses or injection of free minimal MHC-I peptides can paradoxically delete high-affinity CD8⁺ T-cell responses in vivo.

Trogocytic Fratricide in Anti-CD19 and Anti-BCMA CAR-T Therapy

In 2019, Mohamad Hamieh, Michel Sadelain, and colleagues demonstrated in Nature that high-affinity CAR-T cells targeting CD19 (in B-cell acute lymphoblastic leukemia) or BCMA (in multiple myeloma) actively extract CD19 or BCMA proteins from tumor cells via CAR-mediated trogocytosis and incorporate them into the CAR-T cell plasma membrane. This trogocytic transfer causes two deleterious consequences:

1. Reversible Antigen Escape on Tumor Cells: The leukemia cell loses surface CD19 density below the threshold required for CAR recognition, surviving as a "CD19-low" escape variant without acquiring genetic CD19 mutations.
2. CAR-T Cell Fratricide and Exhaustion: The CD19⁺ trogocytic CAR-T cell is recognized as a target by neighboring anti-CD19 CAR-T cells, which kill their sibling CAR-T cell via perforin/granzyme B release and drive tonic signaling and PD-1/LAG-3/TIM-3 exhaustion across the surviving CAR-T cohort.

Engineering Fratricide-Resistant CAR-T Cells for T-Cell Malignancies (T-ALL)

Whereas B-cell aplasia caused by anti-CD19 CAR-T therapy is clinically manageable with intravenous immunoglobulin replacement, designing CAR-T cells against T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphomas faces a fundamental barrier: the best lineage targets on malignant T blasts—CD7, CD5, CD3ε, and TCRαβ—are also expressed on the healthy autologous or allogeneic T cells used to manufacture the CAR-T product. Without intervention, transducing T cells with an anti-CD7 or anti-CD5 CAR triggers immediate, total CAR-T fratricide in the culture bioreactor.

To abolish pan-T-cell CAR fratricide, translational immunologists have developed four clinical-grade engineering strategies:

1. CRISPR-Cas9 or Cytosine/Adenine Base Editing of CD7, CD5, and TRAC: Multiplexed cytosine or adenine base editors (CBE/ABE) convert specific codons in CD7, TRBC1/2 (or TRAC), and CD52 into premature stop codons or splice-site disruptions without creating double-strand DNA breaks or chromosomal translocations. In 2022–2023, Waseem Qasim, Robert Chiesa, and colleagues reported in the New England Journal of Medicine that off-the-shelf base-edited anti-CD7 CAR-T cells (BE-CAR7, with base-edited knockout of CD7, TRAC, and CD52) completely evaded fratricide and induced molecular remissions in pediatric patients with relapsed/refractory T-ALL.
2. Protein Expression Blockers (PEBLs / ER Retention): Developed by Dario Campana and colleagues (2017), T cells are co-transduced with an anti-CD7 single-chain variable fragment (scFv) fused to an endoplasmic reticulum (ER)/Golgi retention sequence (KDEL or KKXX). The PEBL captures endogenous CD7 polypeptides inside the ER lumen before they can traffic to the cell surface, rendering the T cells surface-CD7-negative and fratricide-resistant without genomic editing.
3. Natural Selection / Pharmacological Kinase Inhibition During Expansion: Culturing anti-CD7 or anti-CD5 CAR-T cells in the presence of reversible tyrosine kinase inhibitors (dasatinib and ibrutinib, which transiently block LCK/ITK CAR phosphorylation during ex vivo expansion) or isolating naturally occurring CD7⁻ T-cell subsets prevents fratricide during manufacturing.
4. TRBC1 vs. TRBC2 Clonal Discrimination: Developed by Paul M. Maciocia and Martin Pule (2017), because every αβ T cell expresses either the T-cell receptor β-chain constant region 1 (TRBC1) or TRBC2 (roughly 35%:65% ratio in normal T cells), a monoclonal T-cell lymphoma is uniformly TRBC1⁺ or TRBC2⁺. Selecting or sorting the opposite compartment yields fratricide-free CAR-T cells that eradicate the malignant clone while sparing half of the normal T-cell repertoire.

How does trogocytosis cause CD8⁺ cytotoxic T cells to kill one another?

When an activated CD8⁺ cytotoxic T lymphocyte (CTL) binds its cognate peptide–MHC class I (pMHC-I) complex on a dendritic cell or target cell, the TCR physically pulls a fragment of the target cell membrane—including intact pMHC-I complexes—onto the CTL's own surface (trogocytosis). Because the CTL is now "cross-dressed" with the exact viral or tumor pMHC-I antigen recognized by its own clone, neighboring sibling CTLs bind those acquired pMHC-I complexes and release perforin and granzyme B, lysing the cross-dressed CTL.

Why is fratricide a major obstacle in CAR-T cell therapy for T-cell leukemia (T-ALL)?

Unlike B-cell leukemias—where CAR-T cells target B-cell-specific proteins like CD19 or CD22 that are absent from T cells—malignant T-ALL blasts express surface antigens (CD7, CD5, and CD3) that are also present on the surface of the normal T cells used to manufacture CAR-T cells. As soon as a T cell expresses an anti-CD7 CAR, it binds CD7 on neighboring CAR-T cells (and on itself), triggering mutual perforin/granzyme killing (fratricide) that destroys the cell product before it can be infused into the patient.

Why is CRISPR base editing preferred over standard Cas9 nuclease cutting when engineering fratricide-resistant CAR-T cells?

Creating universal "off-the-shelf" anti-CD7 CAR-T cells requires simultaneously knocking out at least three genes (CD7 to prevent fratricide, TRAC to prevent graft-versus-host disease, and CD52 to resist alemtuzumab conditioning). Standard CRISPR-Cas9 endonucleases cut both strands of DNA at all three loci simultaneously, which frequently causes megabase-scale chromosomal translocations and dicentric chromosomes when broken ends are misjoined by non-homologous end joining. Cytosine and adenine base editors chemically deaminate a single nucleotide to introduce a premature stop codon or disrupt a splice site without generating double-strand DNA breaks, eliminating interchromosomal translocations.

1. Huang, J. F., Yang, Y., Sepulveda, H., Shi, W., Hwang, I., Peterson, P. A., Jackson, M. R., Sprent, J., & Cai, Z. (1999). "TCR-Mediated Internalization of Peptide-MHC Complexes Acquired by T Cells." Science, 286(5441), 952–954. https://doi.org/10.1126/science.286.5441.952
2. Hamieh, M., Dobrin, A., Cabriolu, A., van der Stegen, S. J. C., Giavridis, T., Mansilla-Soto, J., Eyquem, J., Zhao, Z., Whitlock, B. M., Miele, M. M., Li, Z., Cunanan, K. M., Huse, M., Hendrickson, R. C., Wang, X., Rivière, I., & Sadelain, M. (2019). "CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape." Nature, 568(7750), 112–116. https://doi.org/10.1038/s41586-019-1054-1
3. Png, Y. T., Vinanica, N., Kamiya, T., Shimasaki, N., Coustan-Smith, E., & Campana, D. (2017). "Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies." Blood Advances, 1(25), 2348–2360. https://doi.org/10.1182/bloodadvances.2017009928
4. Chiesa, R., Georgiadis, C., Syed, F., Zhan, H., Etuk, A., Gkazi, S. A., Preece, R., Ottaviano, G., Braybrook, T., Chu, J., Kubat, A., Adams, S., Thomas, R., Gilmour, K., O'Connor, D., Vora, A., & Qasim, W. (2023). "Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia." New England Journal of Medicine, 389(10), 899–910. https://doi.org/10.1056/NEJMoa2300709